CERo Therapeutics Holdings, Inc. (CERO)

CERO Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021
Selling, General & Admin	2.39	2.13	2.48
Research & Development	5.29	9.85	9.14
Operating Expenses	7.68	11.97	11.62
Operating Income	-7.68	-11.97	-11.62
Other Expense / Income	-0.39	-0.14	-0.99
Pretax Income	-7.29	-11.83	-10.63
Net Income	-7.29	-11.83	-10.63
Shares Outstanding (Basic)	9	9	9
Shares Outstanding (Diluted)	9	9	9
Shares Change	0.93%	-0.08%	-
EPS (Basic)	-0.80	-1.32	-1.18
EPS (Diluted)	-0.80	-1.32	-1.18
Free Cash Flow	-5.79	-12.4	-10.71
Free Cash Flow Per Share	-0.64	-1.38	-1.19
EBITDA	-6.17	-10.76	-9.89
Depreciation & Amortization	1.12	1.07	0.74
EBIT	-7.29	-11.83	-10.63

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).